Peptonic Medical (publ) (“Peptonic” or “Company”) today announced that it has entered an agreement with Shijiazhuang Yuanjia Biotechnology Co. Ltd. (“Yuanjia Bio”) concerning the registration, marketing, sales and distribution of VagiVital® in the People’s Republic of China (PRC). Under the agreement, Yuanjia Bio is granted the exclusive commercial rights to VagiVital® in PRC. In return, Yuanjia Bio has committed to annual minimum purchase volumes of VagiVital® and to bear all costs of registration and the commercialization of the product. Upon signature of the agreement, Yuanjia Bio will make an initial payment of EUR 125,000 to Peptonic as a partial pre-payment of the first commercial order of VagiVital®. No further details regarding the financial terms of the agreement have been disclosed.
– This is extremely good news for Peptonic, says Dr Johan Inborr, CEO of Peptonic Medical. Yuanjia Bio has the resources and competence required to successfully launch VagiVital in China, and we are both pleased and proud to have them as our partner.
The process of obtaining marketing approval for VagiVital®may take up to 18 months, if a local clinical trial is required. In the meantime, Yuanjia Bio will investigate the possibility of selling VagiVital® via the so called Cross Border E-Commerce (CBEC) on-line platform. CBEC sales is possible without a formal marketing approval of the product, and would primarily serve to raise awareness of the brand among the target patient groups.
– The reason we signed this agreement with Peptonic is that the vaginal atrophy treatment products have great potential in the Chinese market. Most doctors and patients do not have standard treatment guidelines as a reference, and the market potential has not yet been fully appreciated. Yuanjia Bio is confident that after the product education of our professional marketing team, Peptonic’s VagiVital product will be offered to every patient in need in China., says Dr. Conghai Huang, CEO of Yuanjia Biotechnology.
Through its market research in China, Yuanjia Bio has identified four primary target patient groups for VagiVital®, including e.g. menopausal and post-partum women, with a total number of approximately 415 million women. China’s so called ‘gyneacological inflammatory market’ was estimated to reach 26.9 billion yuan (approx. 3.5 billion Euro) in sales in 2018. Between 2013 and 2017, this market grew at a rate of 7.6 percent annually.
For more information, please contact;
Johan Inborr, CEO
Mobile: +46 708 853 893
This information is information that Peptonic Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 25th July 2019.
VagiVital® is a patent pending hormone free self-care product for the treatment of vaginal atrophy and vaginal dryness. The product has been tested in randomised clinical studies (vaginal atrophy) with very positive results both for objective (vaginal pH and proportion of superficial cells in the vaginal mucosa) and subjective (most bothersome symptoms, such as vaginal dryness, vaginal irritation/itching, dyspareunia and dysuria) parameters. The magnitude of symptom relief is on par with that demonstrated with e.g. prescription estrogen based products on the market today. It was very well tolerated and caused no serious adverse effects.
VagiVital® was launched in Sweden as a non-prescription self-care product in July 2018 (seewww.vagivital.com).
About Peptonic Medical
Peptonic Medical is an innovative Swedish medical development company. Its vision is to offer safe and effective treatments and relief for women specific diseases and medical conditions.
VagiVital® is a registered trademark of Peptonic Medical. The product is hormone free and is being commercialised for the non-prescription use for the treatment of vaginal atrophy (VA) and vaginal dryness. The pipeline of Peptonic Medical also includes Vagitocin®, which is an oxytocin-based vaginal gel for the treatment of VA. This product candidate is in clinical development phase 2. The development of Vagitocin® is on hold pending additional data on i.a. the mechanism of action.
Since July 2014, the Peptonic Medical share has been traded on the Spotlight Stock Exchange (www.spotlight.se, ticker: PMED) in Stockholm, Sweden.
For more information: www.peptonicmedical.com
About Shijiazhuang Yuanjia Biotechnology Co. Ltd.
Shijiazhuang Yuanjia Biotechnology Co. Ltd. (‘Yuanjia Bio’) is an international pharmaceutical company established in the Chinese market. The mission of the company to introduce medicinal products, which have been approved in the EU or USA, to China.
The management of Yuanjia Bio is from the senior management team of Jiangxi Jiminkexin – one of the top ten pharmaceutical companies in China. Yuanjia Bio has its own professional and experienced clinical and registration team, and it has a good working relationship with the National Drug Evaluation Center and the Registration Division of the National Medicinal Products Agency (formerly CFDA). Yuanjia Bio has an excellent marketing and sales network in China. The sales network covers all provinces and regions in the country, covering more than 2,000 hospitals. The sales organization is very experienced, and it has an excellent track record in building blockbuster products (more than 1 billion RMB of annual sales). Yuanjia Bio’s core management team has experience from many cases of successfully introducing overseas products to the Chinese market. Furthermore, it has valuable experience from overseas collaborations, such as the licensing agreement with LIDDS AB (Upsala, Sweden) in the field of prostate cancer in 2017.